|1.||Kirsner, Robert S: 4 articles (01/2007 - 12/2002)|
|2.||Falanga, Vincent: 3 articles (07/2006 - 05/2003)|
|3.||Falabella, A F: 3 articles (05/2002 - 10/2000)|
|4.||Edmonds, Michael: 2 articles (01/2010 - 03/2009)|
|5.||DeCarbo, William T: 2 articles (12/2009 - 12/2009)|
|6.||Navsaria, H: 2 articles (06/2007 - 07/2004)|
|7.||Scherschun, Lubomira: 2 articles (12/2003 - 08/2003)|
|8.||Kirsner, R S: 2 articles (12/2001 - 03/2000)|
|9.||Eaglstein, W H: 2 articles (12/2001 - 10/2000)|
|10.||Braathen, L R: 2 articles (01/2001 - 12/2000)|
|1.||Wounds and Injuries (Trauma)
12/01/2009 - "Bioengineered tissue, such as Apligraf (Organogenesis Inc, Canton, Massachusetts), has been shown to be both safe and effective in decreasing healing time and increasing the incidence of complete wound closure. "
02/01/2014 - "Apligraf was shown to be effective in managing the patient's multiple hard-to-heal wounds. "
07/01/2006 - "Several case reports suggest that Apligraf may also be effective in healing acute excisional wounds and complicated surgical defects. "
06/01/2012 - "One study for each of 3 targeted AWCMs (Apligraf [n=130 treatment, n=110 control]; Oasis Wound Matrix [n=62 treatment, n=58 control]; and Talymed [n=22 treatment, n=20 control]) met inclusion criteria. "
03/01/2011 - "The goal of this study was to review clinical experience in treating diabetic and venous stasis wounds with Apligraf or PriMatrix. "
12/01/2002 - "Apligraf-treated skin healed rapidly with good clinical "take." Lack of new skin tears and resultant erosions or ulcer formation suggests improved durability of the Apligraf-treated area occurred. "
12/01/2015 - "The results of this study demonstrate the clinical and resource utilisation superiority of EpiFix compared to Apligraf or standard of care, for the treatment of diabetic ulcers of the lower extremities. "
06/01/2012 - "Ulcer duration exceeded 12 months for 50% of patients in the Apligraf study and was at least 7 months for 47% of patients in the Oasis study; patients with ulcers exceeding 6 months were excluded from the study of Talymed. "
12/01/2003 - "During the Apligraf post-treatment study period, mean ulcer size decreased by -2.37 cm2 per week. "
05/01/2009 - "After covering the ulcer with Apligraf, the skin reconditioned, resulting in fair skin color and a smooth skin surface in all but one case. "
06/01/2006 - "The efficacy of Apligraf in the treatment of diabetic foot ulcers."
01/01/2010 - "Confirmatory data from EU study supports Apligraf for the treatment of neuropathic diabetic foot ulcers."
03/01/2009 - "This study compared the efficacy and safety of Apligraf (Organogenesis, Inc., Canton, MA) in combination with standard therapy versus standard therapy alone in the treatment of neuropathic diabetic foot ulcers. "
03/01/2009 - "Apligraf in the treatment of neuropathic diabetic foot ulcers."
01/01/2003 - "The cost effectiveness of Apligraf treatment of diabetic foot ulcers."
07/01/1999 - "The efficacy of a bilayered, living skin construct (APLIGRAF(R) [Graftskin]) was evaluated in patients (n = 120) with hard- to-heal venous leg ulcers of greater than 1 year's duration. "
12/01/2003 - "Controlled studies have shown that Apligraf(R) (Organogenesis Inc., Canton, USA) is more economical and more effective at healing venous leg ulcers (VLUs) than compression therapy alone. "
12/01/2003 - "Clinical and economic impact of Apligraf for the treatment of nonhealing venous leg ulcers."
05/01/2002 - "The role of graftskin (Apligraf) in difficult-to-heal venous leg ulcers."
08/01/2001 - "Cost-effectiveness of Apligraf in the treatment of venous leg ulcers."
11/01/2000 - "The Apligraf Burn Study Group."
01/01/2001 - "Full-thickness burn of the foot: successful treatment with Apligraf. "
11/01/2000 - "These results indicate that Apligraf(R) is a suitable and clinically effective treatment for burn wounds when applied over meshed autografts. "
06/01/2007 - "They have been incorporated into various tissue-engineered products such as Dermagraft (Advanced BioHealing, La Jolla, CA, U.S.A.) and Apligraf (Novartis, Basel, Switzerland) and used for a variety of clinical applications, including the treatment of burns, chronic venous ulcers and several other clinical applications in dermatology and plastic surgery. "
01/01/2001 - "To the authors' knowledge, there have been no other cases reported of Apligraf use in burn wound coverage of the foot."
|1.||platelet-derived growth factor BB (becaplermin)
|2.||Intercellular Signaling Peptides and Proteins (Growth Factors)
|4.||Platelet-Derived Growth Factor
|7.||Collagen Type I (Type I Collagen)
|10.||Immunosuppressive Agents (Immunosuppressants)
|3.||Tissue Therapy (Cell Therapy)
|4.||Skin Transplantation (Skin Grafting)
|5.||Homologous Transplantation (Allograft)